Notice of Application - 2010
FR Doc 2010-15517[Federal Register: June 28, 2010 (Volume 75, Number 123)]
[Notices]
[Page 36681]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr28jn10-97]
[[Page 36681]]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on April 29, 2010, Alltech
Associates Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of the basic classes of controlled
substances listed in schedules I and II:
| Drug |
Schedule |
| Methcathinone (1237) |
I |
| N-ethylamphetamine (1475) |
I |
| N,N-dimethylamphetamine (1480) |
I |
| 4-methylaminorex (cis isomer) (1590) |
I |
| Alpha-ethyltryptamine (7249) |
I |
| Lysergic acid diethylamide (7315) |
I |
| 4-methylaminorex (cis isomer) (1590) |
I |
| Alpha-ethyltryptamine (7249) |
I |
| Lysergic acid diethylamide (7315) |
I |
| 2,5-dimethoxy-4-(n)-propylthiophenethylamine (7348) |
I |
| Tetrahydrocannabinols (7370) |
I |
| Mescaline (7381) |
I |
| 4-bromo-2,5-dimethoxy-amphetamine (7391) |
I |
| 4-Bromo-2,5-dimethoxyphenethylamine (7392) |
I |
| 4-methyl-2,5-dimethoxy-amphetamine (7395) |
I |
| 2,5-dimethoxyamphetamine (7396) |
I |
| 2,5-dimethoxy-4-ethylamphetamine (7399) |
I |
| 3,4-methylenedioxy amphetamine (7400) |
I |
| N-hydroxy-3,4-methylenedioxyamphetamine (7402) |
I |
| 3,4-methylenedioxy-N-ethylamphetamine (7404) |
I |
| 3,4-methylenedioxymethamphetamine (MDMA) (7405) |
I |
| 4-methoxyamphetamine (7411) |
I |
| Alpha-methyltryptamine (7432) |
I |
| Bufotenine (7433) |
I |
| Diethyltryptamine (7434) |
I |
| Dimethyltryptamine (7435) |
I |
| Psilocybin (7437) |
I |
| Psilocyn (7438) |
I |
| 5-methoxy-N,N-diisopropyltryptamine (7439) |
I |
| N-ethyl-1-phenylcyclohexylamine (7455) |
I |
| 1-(1-phenylcyclohexyl)-pyrrolidine (7458) |
I |
| 1-[1-(2-thienyl)-cyclohexyl]-piperidine (7470) |
I |
| Dihydromorphine (9145) |
I |
| Normorphine (9313) |
I |
| Methamphetamine (1105) |
II |
| 1-phenylcyclohexylamine (7460) |
II |
| Phencyclidine (7471) |
|
| Phenylacetone (8501) |
II |
| 1-piperidinocyclohexanecarbonitrile (8603) |
II |
| Cocaine (9041) |
II |
| Codeine (9050) |
II |
| Dihydrocodeine (9120) |
II |
| Ecgonine (9180) |
II |
| Meperidine intermediate-B (9233) |
II |
| Noroxymorphone (9668) |
II |
The company plans to manufacture high purity drug standards used
for analytical application only in clinical, toxicological, and
forensic laboratories.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than August 27, 2010.
Dated: June 17, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-15517 Filed 6-25-10; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an unofficial version. An official version of this publication may be obtained
directly from the Government Printing Office (GPO). |
